SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2026-- Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the
Dr. Angelov brings extensive industry experience across multiple therapeutic areas SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2026-- Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President
Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and
Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 3, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 25, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present
PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 12, 2026-- Vistagen (Nasdaq: VTGN), a late
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 4, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo Favorable safety and tolerability data were consistent with previous studies Company’s cash preservation measures expected to provide runway
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 1, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced